“The good thing about that was it was bipartisan … But if not, we’ll continue to work … So we’ll be able to, I think we’ll be able to make the PBM reform and other things in that bill ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two ...

The price concessions from the pharmacy come from lower contracted rates that pharmacies must accept in order to participate in the PBM’s pharmacy network. Depending on the way an employer ...

A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs.

The final text saw a number of legislative proposals culled in order to get it over the line, including measures that would have introduced stricter controls over the PBM sector that had been ...

Walgreens is making progress renegotiating contracts with pharmacy benefit managers and selling its VillageMD stake, while continuing to trim down other parts of the business. Walgreens' sale of ...

LITTLE ROCK, Ark. — High drug costs and struggling local pharmacies have become critical challenges for Arkansans. That reality is the very reason that's prompting lawmakers to take action ...

But beneath the surface of this public scrutiny lies the biggest threat to the traditional PBM structure, one that signals a quiet shift in the market: changing demands from employers, unions ...

The FTC’s investigation into PBM practices began in 2022. Last summer, the agency released a scathing interim report on the industry. It detailed how increasing concentration enabled the three ...